NEW YORK, Oct 30 (Reuters) - Amylin Pharmaceuticals Inc said on Friday that its Byetta drug has won U.S. regulatory approval for use as a stand-alone medication to improve glycemic control in adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results